WCN26-4375 EIGHT YEARS OF CANADIAN REAL-WORLD ASSESSMENT OF TOLVAPTAN IN ADPKD: PATIENT REPORTED OUTCOMES FROM THE C-MAJOR STUDY

Read full text Summarise with VIRAT
Authors: Phil McFarlane, Daniel Georges Bichet, Ahsan Alam, Dorothee Oberdhan, Suzy Bubolic, Annick Laplante
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Tolvaptan (Jinarc®) is the first approved treatment in Canada to slow the progression of kidney enlargement and kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD). C-MAJOR is an ongoing, observational, multi-center registry of people with ADPKD treated with tolvaptan, initiated in 2015, as per Health Canada requirements. This analysis describes the impact of tolvaptan on ADPKD-related health-related quality of life (HRQoL) in people with ADPKD in Canada.

Fields of Study & Subjects

Genetic and Kidney Cyst Diseases Tuberous Sclerosis Complex Research Cystic Fibrosis Research Advances

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104336–104336
Publication date
25 March 2026
Language
EN